胃癌组织p16基因蛋白表达的意义

目的　检测 p1 6基因蛋白在胃癌组织、癌旁组织中的表达及其分布特点 ,分析其与胃癌临床病理学特征及预后的关系 .方法　采用 S- P免疫组织化学法对 53例胃癌组织及 35例癌旁组织进行 p1 6蛋白的定位观察 .结果　各病理类型胃癌组织、癌旁组织均有 p1 6基因蛋白表达 .阳性率分别为 62 .3% (33/53)和 88.6% (31 /35) ,阳性细胞的棕黄色颗粒主要位于细胞核 .胃癌 p1 6基因蛋白表达与性别、年龄、肿瘤部位在统计学上无差异 (P>0 .0 5) ;而与组织学类型、病理分级、淋巴结转移、临床病理分期在统计学上有差异 (P<0 .0 5) .p1 6蛋白阳性者 5年生存率 51 .0 %高于 p1 6蛋白阴性者 2 0 .0 % (P<0 .0 5) .结论　 p1 6基因缺失和表达水平的改变与胃癌发生、发展密切相关 ,检测 p1 6基因蛋白表达可作为辅助临床判断胃癌的生物学行为及推测预后的指标     

临床路径护理在缺血性脑卒中病人中的应用研究

目前医疗界面临的两大问题是提高医疗水平和控制医疗成本,解决这两大问题的方法之一就是使用临床路径(clinicalpath,CP)[1]。临床路径是医院内各个学科的专家,对某种疾病或手术方式制定公认的治疗模式,让病人从住院到出院都依此模式治疗,并根据临床路径的结果进行分析,评估每位     

Evaluation of the MagNA Pure LC used with the TRUGENE HBV Genotyping Kit.

BACKGROUND: The current manual sample processing method recommended for use with the TRUGENE HBV Genotyping Kit (TRUGENE HBV; Bayer HealthCare LLC, Tarrytown, NY) is labor-intensive and may be prone to specimen cross-contamination. Recent evaluations of the MagNA Pure LC (MP; Roche Applied Science, Indianapolis, IN) suggest that it is suitable for automated, contamination-free extraction and purification of viral nucleic acids from large-volume (1.0 mL) serum or plasma specimens. OBJECTIVES: We evaluated the MP Total Nucleic Acid Isolation Kit--Large Volume (Roche Applied Science) in conjunction with TRUGENE HBV to establish the analytical sensitivity (threshold titer) of the assay, in HBV DNA International Units (IU)/mL, for obtaining consistent, interpretable sequence data from TRUGENE HBV. STUDY DESIGN: HBV analytical standards, prepared as 10 replicates (1.0 mL each) at each of the following concentrations: 200, 1000, 5000, and 10,000 IU/mL, were processed by MP and analyzed by TRUGENE HBV according to manufacturer's instructions. Performance of TRUGENE HBV used in conjunction with MP sample processing was evaluated further using 22 clinical serum specimens containing low titers of HBV DNA. RESULTS: All replicates of HBV analytical standards at 1000, 5000, and 10,000 IU/mL yielded interpretable TRUGENE HBV sequences, whereas interpretable sequences were obtained in 90% (9 of 10) of the replicates at 200 IU/mL. TRUGENE HBV sequences were interpretable in 86% (19 of 22) of the clinical specimens studied. CONCLUSIONS: MP sample processing is efficient and suitable for use with TRUGENE HBV. When combined with MP sample processing, TRUGENE HBV yielded interpretable sequences from HBV analytical standards and clinical serum specimens with HBV DNA titers of > or =200 IU/mL.     

Pancreatic cancer–Palliative therapy: surgery (bypass/resection)

Objective: We compare the outcome of palliative pancreaticoduodenectomy and palliative surgical bypass in patients with advanced pancreatic carcinoma in our hospital. Recent published related articles are also reviewed. Methods: A respective analysis was performed comparing the perioperative parameters and outcome of 20 patients who underwent pancreaticoduodenectomy with a gross suspected cancer residue and 30 patients who underwent a surgical bypass, all of the patients were diagnosed as in advanced stages intra-operatively. Results: The two groups were comparable with patient characteristics, including age, gender, initial symptoms and concomitant major organ diseases. Tumors are similar in size and intra-operatively diagnosed as in advanced stages in both groups. All of the patients in the resection group were microscopically proved having cancer residue. One postoperative mortality occurred in the resection group (5%), zero in the bypass group (P > 0.05). Overall complications were significantly higher in the resection group (30% vs. 0, P < 0.01), including 2 patients developed Acute Respiratory Distress Syndrome (ARDS), zero in the bypass group (P < 0.01); hemorrhage and transfusions in the resection group were much more than that in the bypass group (P < 0.05). Hospital stay after resection was significantly longer than bypass (20 vs. 12 days, P < 0.01). Hospital fee after resection was 4 times more than after bypass (median 61.500 vs. 15. 300 yuan, P < 0.01). Survival was significantly longer after resection (median 12.2 vs. 7.1 months, P < 0.01). Conclusion: Our results show that palliative resection in advanced pancreatic carcinoma lengthens the survival time of the patients, but this is paid for significantly higher complications than bypass.     

可调节型充气体位垫的制作和应用

手术中常用体位垫来调整体位及预防褥疮,但以往使用的软垫、海绵垫等却不可根据手术及术中的要求来调节高度,我科对其进行研究并利用现有材料,将其改进制成可调节型充气体位垫,投入临床试用,效果较好。现介绍如下。1材料与制作取上海百特医疗用品有限公司生产的3L容量的氯化钠溶液软包装袋一个,将其中一个出口封闭,使其不漏气。将一根长30cm~50cm长的橡胶管固定于另一个出口,使其不漏气,并将输血器调节器穿于橡胶管上,调节滚轴,起开关作用。连接气压止血器充气,即成可调节型充气调节体位垫。2使用方法根据手术要求将橡胶管连接于气压止血器…     

Omnitets EZ(R)及BIOSEN 5030临床验证报告

本文通过使用 Omnitets EZ 电子感应血糖仪及 BIOSEN 5030自动血糖/乳酸分析仪对糖尿病人和正常人血糖进行测定,从而对其精确性进行评估,探讨其临床应用的可能性.     

两种微创方法治疗股骨颈骨折的临床对照试验

目的分别应用三针锁针加压器外固定和空心拉力钉内固定疗法治疗股骨颈骨折,探讨股骨颈骨折最佳治疗方法.方法应用三针锁针加压器外固定治疗股骨颈骨折63例,其中男24例,女39例;年龄55～89岁,平均(64.5±3.2)岁;Garderl Ⅰ型2例,Ⅱ型15例,Ⅲ型38例,Ⅳ型8例.应用空心拉力钉内固定治疗63例,其中男29例,女34例;年龄45～76岁,平均(62.2±2.9)岁;Garden Ⅰ型4例,Ⅱ型24例,Ⅲ型28例,Ⅳ型7例.对其疗效进行分析.结果126例除2例死亡外均得到随访.115例愈合,其中10例股骨头坏死.外固定组愈合58例,股骨头坏死4例,死亡1例;内固定组愈合57例,股骨头坏死6例,死亡1例.根据Harris功能评定标准评价疗效,外固定组62例中优24例,良26例,可8例,差4例,优良率80.65%;内固定组62例中优23例,良27例,可6例,差6例,优良率80.65%.Harris评分外固定组平均(80.40±1.21)分,内固定组平均(79.14±1.47)分,两组Harris评分比较差异无统计学意义(P＞0.05).结论采用内外固定治疗股骨颈骨折疗效无明显差异,但外固定创伤小、费用低、可早期离床;而采用拉力钉内固定器医疗成本高,卧病时间相对较长,且需二次手术取内固定钉.     

腰麻硬膜外联合麻醉在全产程中的镇痛效果及对母婴的影响

①目的　探讨腰麻硬膜外联合麻醉在全产程中的镇痛效果以及对母婴的影响。②方法　选择ASAⅠ～Ⅱ级、无禁忌证的单胎头位临产初产妇 30 0例 ,随机分为腰硬组 (腰麻硬膜外联合麻醉 )、硬外组 (硬膜外麻醉 )和对照组 (未用任何麻醉方法 )各 10 0例。行L2～ 3 椎间隙一点穿刺并一次成功。分别观察镇痛效果、起效时间、用药量、副作用、产程、分娩方式及母婴情况。③结果　腰硬组镇痛效果、起效时间以及用药量明显优于硬外组(uc=5 .34,t=16 .92～ 2 9.6 9,P <0 .0 1) ;与对照组比较 ,宫颈扩张加速 ,第一产程明显缩短 ,而第二产程延长 (t =3.34～ 4 8.4 9,P <0 .0 1) ,剖宫产率明显下降 ,而阴道助产率增高 ,胎儿宫内窘迫的发生率下降 (χ2 =6 .82～ 2 0 .35 ,P <0 .0 1)。④结论　腰麻硬膜外联合麻醉用于分娩镇痛优于硬膜外麻醉 ,是一种安全有效、更适合全产程镇痛的麻醉方法。